Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic. Issue 1 (18th June 2021)

• Record Type: Journal Article
• Authors: Lozano-Sanchez, Fernando; Ursu, Renata; Di-Stefano, Anna Luisa; Ducray, Francois; Younan, Nadia; Touat, Mehdi; Groh, Matthieu; Agguini, Hanane; Belin, Catherine; Garnier, Luois; Delattre, Jean-Yves; Carpentier, Antoine; Idbaih, Ahmed
• Is Part Of: Neuro-oncology advances. Volume 3:Issue 1(2021)
• Publication Date: 2021-06-18
• Subjects: COVID-19 -- diffuse glioma -- outcome -- prognosis -- SARS-CoV2; 616.99481
• DOI: 10.1093/noajnl/vdab078
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Background: Little is known about diffuse glioma patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Methods: We performed a descriptive and retrospective analysis of 41 diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the COVID-19 pandemic. Results: Confusion with or without fever was the most common neurological symptom (32%) supporting SARS-CoV2 testing in glioma patients with acute and unexplained confusion. Sixteen patients (39%) died after a median delay of 13 days. While multiple clinical, biological, and pathological features, COVID-19- or diffuse glioma-related, at hospital admission appeared to have a pejorative prognostic impact, none was significantly associated with death. Oncological treatments were interrupted at COVID-19 diagnosis and re-initiated with a median delay of 30 days after the end of COVID-19 symptoms. Conclusions: Interestingly, our retrospective study describes for the first time the characteristics of a cohort of diffuse glioma patients with symptomatic COVID-19. Diffuse glioma patients with poorly symptomatic COVID-19 did not come to the attention of physicians and were not enrolled in the study skewing the denominator for prognostic analysis. Further studies are warranted to specify prognosis of overall population of diffuse glioma patients with COVID-19, including asymptomatic patients, and interactions of prognostic factors of both COVID-19 and diffuse gliomas.